775 related articles for article (PubMed ID: 26373574)
1. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients.
Sun Y; Li G; Zhu W; He Q; Liu Y; Chen X; Liu J; Lin J; Han-Zhang H; Yang Z; Lizaso A; Xiang J; Mao X; Liu H; Gao Y
Ann Transl Med; 2020 Oct; 8(20):1290. PubMed ID: 33209870
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
4. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive identification of
Gu W; Yang J; Wang Y; Xu J; Wang X; Du F; Hu X; Guo H; Song C; Tao R; Zhang X
Am J Cancer Res; 2021; 11(8):3893-3906. PubMed ID: 34522456
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
9. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
10. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
[TBL] [Abstract][Full Text] [Related]
11. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
13. FGF receptors: cancer biology and therapeutics.
Katoh M; Nakagama H
Med Res Rev; 2014 Mar; 34(2):280-300. PubMed ID: 23696246
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
15. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
Hughes SE
Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptors, developmental corruption and malignant disease.
Kelleher FC; O'Sullivan H; Smyth E; McDermott R; Viterbo A
Carcinogenesis; 2013 Oct; 34(10):2198-205. PubMed ID: 23880303
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract][Full Text] [Related]
18. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
19. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
20. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK; Hong F; Vaklavas C; Cheng HH; Hammerman P; Mitchell EP; Zwiebel JA; Ivy SP; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Mansfield A; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Jul; 38(21):2407-2417. PubMed ID: 32463741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
